Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alcon Research
About 470 adults with OAG or OHT will be randomly divided into 2 groups. One group will use the new Reformulated PG324 eye drops, and the other group will use the marketed PG324 eye drops. This study will be double-masked, so neither the researcher nor the participant will know which eye drop was administered. The expected individual duration of participation is approximately 3 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of open-angle glaucoma or ocular hypertension in both eyes;
Unmedicated intraocular pressure measurements in the study eye as specified in the protocol;
Corrected distance visual acuity equal to or better than 20/100 in the study eye.
You may not be if
Current use of more than 2 ocular hypotensive medications within 30 days;
Intraocular pressure greater than 36 millimeters mercury (mmHg) at Screening;
Use of topical ocular medication of any kind within 5 days of Screening or throughout the study with the exception of ocular hypotensive medications (must be washed out).